The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Revishchin A.V.

Institute of Higher Nervous Activity and Neurophysiology

Pavlova G.V.

Institute of Higher Nervous Activity and Neurophysiology;
Burdenko Neurosurgical Center

Antidepressants as additional drugs for human brain gliomas

Authors:

Revishchin A.V., Pavlova G.V.

More about the authors

Journal: Burdenko's Journal of Neurosurgery. 2024;88(6): 97‑102

DOI: 10.17116/neiro20248806197

Views: 770

Downloaded: 21

Buy PDF (RU) for 300₽
Download PDF (EN)
Contact the author
Table of contents

ANTIDEPRESSANTS AS ADDITIONAL DRUGS FOR HUMAN BRAIN GLIOMAS
ANTIDEPRESSANTS AS ADDITIONAL DRUGS FOR HUMAN BRAIN GLIOMAS

To cite this article:

Revishchin AV, Pavlova GV. Antidepressants as additional drugs for human brain gliomas. Burdenko's Journal of Neurosurgery. 2024;88(6):97‑102. (In Russ., In Engl.)
https://doi.org/10.17116/neiro20248806197

 
Подписка 2025-2 (Burdenko's Journal of Neurosurgery)
 
МСФ на ЯМ
Close metadata
Recommended articles:
Info­rmation support for the bioresource collection: a biological info­rmation system «NeuroOnc». Burdenko's Journal of Neurosurgery. 2024;(3):65-73
PET/CT with 11C-methionine as a predictor of disease-free survival in patients with IDH1 wild type diffuse glioma. Burdenko's Journal of Neurosurgery. 2024;(5):6-13
Human glioma mali­gnancy grade and migratory capa­city depe­nding on expression of GDNF isoforms in vitro. Burdenko's Journal of Neurosurgery. 2024;(6):31-38
Pathogenetic basis of modern approaches to the therapy of sleep diso­rders in the clinic of depression. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(4):69-74
Pharmacogenomic and pharmacometabolomic biomarkers of the effi­cacy and safety of anti­depressants: focus on sele­ctive sero­tonin reuptake inhi­bitors. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):26-35
Mela­tonergic anti­depressant agomelatine: augmentation of anti­psychotic drugs in treatment of post-schizophrenic depression. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(8):5-12
Sero­tonin syndrome: focus on opioid analgesics. Russian Journal of Pain. 2024;(3):98-106
Pathogenetic inte­rrelations of hypo­gonadism and depression in men. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(1):17-23

Glioblastoma (GB) is the most aggressive malignant brain tumor. To date, there is no optimal treatment approach for this disease. Antidepressants with antitumor effects are one of the new therapeutic directions. A distinctive feature of these drugs is their approval for clinical practice in the treatment of depressive disorders.

OBJECTIVE

To analyze available literature data on mechanisms of antitumor action and advisability of antidepressants for GB.

MATERIAL AND METHODS

We reviewed the databases using the keywords «glioma», «antidepressants», «drug repurposing».

RESULTS

According to numerous preclinical studies, activity of antidepressants at the cellular level is aimed at enhancing apoptosis and autophagy, inhibiting the cell cycle, differentiating and/or maintaining the stem cell status, as well as migrating tumor cells.

CONCLUSION

Available data can substantiate further experimental and clinical studies, as well as searching for therapeutic combinations using antidepressants for the treatment of human gliomas.

Keywords:

glioma
antidepressants
drug repurposing

Authors:

Revishchin A.V.

Institute of Higher Nervous Activity and Neurophysiology

Pavlova G.V.

Institute of Higher Nervous Activity and Neurophysiology;
Burdenko Neurosurgical Center

Received:

06.09.2024

Accepted:

20.09.2024

List of references:

  1. Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical r&d efficiency. Nature Reviews Drug Discovery. 2012;11:191-200.  https://doi.org/10.1038/nrd3681
  2. Hodos RA, Kidd BA, Shameer K, Readhead BP, Dudley JT. In silico methods for drug repurposing and pharmacology. Wiley Interdisciplinary Reviews: Systems Biology and medicine. 2016;8:186-210.  https://doi.org/10.1002/wsbm.1337
  3. Zhang Y, Zheng Q, Zhou Y, Liu S. Repurposing clinical drugs as adometdc inhibitors using the scar strategy. Frontiers in Pharmacology. 2020;11:248.  https://doi.org/10.3389/fphar.2020.00248
  4. Baker NC, Ekins S, Williams AJ, Tropsha A. A bibliometric review of drug repurposing. Drug Discovery Today. 2018;23:661-672.  https://doi.org/10.1016/j.drudis.2018.01.018
  5. King JL, Benhabbour SR. Glioblastoma multiforme-a look at the past and a glance at the future. Pharmaceutics. 2021;13(7):1053. https://doi.org/10.3390/pharmaceutics13071053
  6. Minniti G, Amelio D, Amichetti M, Salvati M, Muni R, Bozzao A, Lanzetta G, Scarpino S, Arcella A, Enrici RM. Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide. Radiotherapy and Oncology. 2010;97:377-381.  https://doi.org/10.1016/j.radonc.2010.08.020
  7. Pinkiewicz M, Pinkiewicz M, Walecki J, Zaczynski A, Zawadzki M. Breaking barriers in neuro-oncology: A scoping literature review on invasive and non-invasive techniques for blood-brain barrier disruption. Cancers. 2024;16(1):236.  https://doi.org/10.3390/cancers16010236
  8. van der Meer PB, Dirven L, Hertler C, Boele FW, Batalla A, Walbert T, Rooney AG, Koekkoek JAF. Depression and anxiety in glioma patients. Neuro-Oncology Practice. 2023;10:335-343.  https://doi.org/10.1093/nop/npad019
  9. Shi C, Lamba N, Zheng LJ, Cote D, Regestein QR, Liu CM, Tran Q, Routh S, Smith TR, Mekary RA, Broekman MLD. Depression and survival of glioma patients: A systematic review and meta-analysis. Clinical Neurology and Neurosurgery. 2018;172:8-19.  https://doi.org/10.1016/j.clineuro.2018.06.016
  10. Tan SK, Jermakowicz A, Mookhtiar AK, Nemeroff CB, Schurer SC, Ayad NG. Drug repositioning in glioblastoma: A pathway perspective. Frontiers in Pharmacology. 2018;9:218.  https://doi.org/10.3389/fphar.2018.00218
  11. Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. British Journal of Pharmacology. 2007;151:737-748.  https://doi.org/10.1038/sj.bjp.0707253
  12. Jeon SH, Kim SH, Kim Y, Kim YS, Lim Y, Lee YH, Shin SY. The tricyclic antidepressant imipramine induces autophagic cell death in u-87mg glioma cells. Biochemical and Biophysical Research Communications. 2011;413:311-317.  https://doi.org/10.1016/j.bbrc.2011.08.093
  13. Hsu FT, Chiang IT, Wang WS. Induction of apoptosis through extrinsic/intrinsic pathways and suppression of erk/nf-kappab signalling participate in anti-glioblastoma of imipramine. Journal of Cellular and Molecular Medicine. 2020;24:3982-4000. https://doi.org/10.1111/jcmm.15022
  14. Wang Y, Wang X, Wang X, Wu D, Qi J, Zhang Y, Wang K, Zhou D, Meng QM, Nie E, Wang Q, Yu RT, Zhou XP. Imipramine impedes glioma progression by inhibiting yap as a hippo pathway independent manner and synergizes with temozolomide. Journal of Cellular and Molecular Medicine. 2021;25:9350-9363. https://doi.org/10.1111/jcmm.16874
  15. Alburquerque-Gonzalez B, Bernabe-Garcia M, Montoro-Garcia S, Bernabe-Garcia A, Rodrigues PC, Ruiz Sanz J, Lopez-Calderon FF, Luque I, Nicolas FJ, Cayuela ML, Salo T, Perez-Sanchez H, Conesa-Zamora P. New role of the antidepressant imipramine as a fascin1 inhibitor in colorectal cancer cells. Experimental and Molecular Medicine. 2020;52:281-292.  https://doi.org/10.1038/s12276-020-0389-x
  16. Histological and clinical effects of imipramine in the treatment of patients with cancer over-expressing fascin1. European Union Clinical Trials Register, 2021. https://www.clinicaltrialsregister.eu/ctr-search/search?query=HITCLIF
  17. Zhang H, Cong QX, Zhang SG, Zhai XW, Li HF, Li SQ. High expression levels of fascin-1 protein in human gliomas and its clinical relevance. Open Medicine (Wars). 2018;13:544-550.  https://doi.org/10.1515/med-2018-0080
  18. Munson JM, Fried L, Rowson SA, Bonner MY, Karumbaiah L, Diaz B, Courtneidge SA, Knaus UG, Brat DJ, Arbiser JL, Bellamkonda RV. Anti-invasive adjuvant therapy with imipramine blue enhances chemotherapeutic efficacy against glioma. Science Translational Medicine. 2012;4:127ra136. https://doi.org/10.1126/scitranslmed.3003016
  19. Kolesnikova V, Revishchin A, Fab L, Alekseeva A, Ryabova A, Pronin I, Usachev DY, Kopylov A, Pavlova G. Gqicombi application to subdue glioma via differentiation therapy. Frontiers in Oncology. 2024;14:1322795. https://doi.org/10.3389/fonc.2024.1322795
  20. Pavlova G, Kolesnikova V, Samoylenkova N, Drozd S, Revishchin A, Shamadykova D, Usachev DY, Kopylov A. A combined effect of g-quadruplex and neuro-inducers as an alternative approach to human glioblastoma therapy. Frontiers in Oncology. 2022;12:880740. https://doi.org/10.3389/fonc.2022.880740
  21. Bielecka-Wajdman AM, Lesiak M, Ludyga T, Sieron A, Obuchowicz E. Reversing glioma malignancy: A new look at the role of antidepressant drugs as adjuvant therapy for glioblastoma multiforme. Cancer Chemotherapy and Pharmacology. 2017;79:1249-1256. https://doi.org/10.1007/s00280-017-3329-2
  22. Chryplewicz A, Scotton J, Tichet M, Zomer A, Shchors K, Joyce JA, Homicsko K, Hanahan D. Cancer cell autophagy, reprogrammed macrophages, and remodeled vasculature in glioblastoma triggers tumor immunity. Cancer Cell. 2022;40(10):1111-1127.e9.  https://doi.org/10.1016/j.ccell.2022.08.014
  23. Troib A, Azab AN. Effects of psychotropic drugs on nuclear factor kappa b. European Reviews for Medical and Pharmacological Sciences. 2015;19:1198-1208.
  24. Parker KA, Pilkington GJ. Apoptosis of human malignant glioma-derived cell cultures treated with clomipramine hydrochloride, as detected by annexin-v assay. Radiology and Oncology. 2006;40. (2). Retrieved from https://www.radioloncol.com/index.php/ro/article/view/1265
  25. Bilir A, Erguven M, Yazihan N, Aktas E, Oktem G, Sabanci A. Enhancement of vinorelbine-induced cytotoxicity and apoptosis by clomipramine and lithium chloride in human neuroblastoma cancer cell line sh-sy5y. Journal of Neurooncology. 2010;100:385-395.  https://doi.org/10.1007/s11060-010-0209-6
  26. Xia Z, Depierre JW, Nassberger L. The tricyclic antidepressants clomipramine and citalopram induce apoptosis in cultured human lymphocytes. Journal of Pharmacy and Pharmacology. 1996;48:115-116.  https://doi.org/10.1111/j.2042-7158.1996.tb05889.x
  27. Pollard SM, Yoshikawa K, Clarke ID, Danovi D, Stricker S, Russell R, Bayani J, Head R, Lee M, Bernstein M, Squire JA, Smith A, Dirks P. Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell. 2009;4:568-580.  https://doi.org/10.1038/bjc.2016.109
  28. Sarrouilhe D, Mesnil M. Serotonin and human cancer: A critical view. Biochimie. 2019;161:46-50.  https://doi.org/10.1016/j.biochi.2018.06.016
  29. Cheer SM, Goa KL. Fluoxetine: A review of its therapeutic potential in the treatment of depression associated with physical illness. Drugs. 2001;61:81-110.  https://doi.org/10.2165/00003495-200161010-00010
  30. Song T, Li H, Tian Z, Xu C, Liu J, Guo Y. Disruption of nf-kappab signaling by fluoxetine attenuates mgmt expression in glioma cells. OncoTargets and Therapy. 2015;8:2199-2208. https://doi.org/10.2147/OTT.S85948
  31. Ma J, Yang YR, Chen W, Chen MH, Wang H, Wang XD, Sun LL, Wang FZ, Wang DC. Fluoxetine synergizes with temozolomide to induce the chop-dependent endoplasmic reticulum stress-related apoptosis pathway in glioma cells. Oncology Reports. 2016;36:676-684.  https://doi.org/10.3892/or.2016.4860
  32. Hosseinimehr SJ, Najafi SH, Shafiee F, Hassanzadeh S, Farzipour S, Ghasemi A, Asgarian-Omran H. Fluoxetine as an antidepressant medicine improves the effects of ionizing radiation for the treatment of glioma. Journal of Bioenergetics and Biomembranes. 2020;52:165-174.  https://doi.org/10.1007/s10863-020-09833-9
  33. Bi J, Khan A, Tang J, Armando AM, Wu S, Zhang W, Gimple RC, Reed A, Jing H, Koga T, Wong IT, Gu Y, Miki S, Yang H, Prager B, Curtis EJ, Wainwright DA, Furnari FB, Rich JN, Cloughesy TF, Kornblum HI, Quehenberger O, Rzhetsky A, Cravatt BF, Mischel PS. Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug. Cell Reports. 2021;37:109957. https://doi.org/10.1016/j.celrep.2021.109957
  34. Tzadok S, Beery E, Israeli M, Uziel O, Lahav M, Fenig E, Gil-Ad I, Weizman A, Nordenberg J. In vitro novel combinations of psychotropics and anti-cancer modalities in u87 human glioblastoma cells. International Journal of Oncology. 2010;37:1043-1051. https://doi.org/10.3892/ijo_00000756
  35. Xu D, Wang C, Zhu X, Zhao W, Jiang B, Cui S, Sun Y, Cui Z. The antidepressant-like effects of fluvoxamine in mice involve the mtor signaling in the hippocampus and prefrontal cortex. Psychiatry Research. 2020;285:112708. https://doi.org/10.1016/j.psychres.2019.112708
  36. Hayashi K, Michiue H, Yamada H, Takata K, Nakayama H, Wei FY, Fujimura A, Tazawa H, Asai A, Ogo N, Miyachi H, Nishiki T, Tomizawa K, Takei K, Matsui H. Fluvoxamine, an anti-depressant, inhibits human glioblastoma invasion by disrupting actin polymerization. Scientific Reports. 2016;6:23372. https://doi.org/10.1038/srep23372
  37. Thakerar A, Simadri K, Alexander M, Fullerton S. Paroxetine for the treatment of intractable and persistent cough in patients diagnosed with cancer. Journal of Oncology Pharmacy Practice. 2019;26:803-808.  https://doi.org/10.1177/1078155219870594
  38. Levkovitz Y, Gil-Ad I, Zeldich E, Dayag M, Weizman A. Differential induction of apoptosis by antidepressants in glioma and neuroblastoma cell lines: Evidence for p-c-jun, cytochrome c, and caspase-3 involvement. Journal of Molecular Neuroscience. 2005;27:29-42.  https://doi.org/10.1385/JMN:27:1:029
  39. Woroniecka KI, Rhodin KE, Chongsathidkiet P, Keith KA, Fecci PE. T-cell dysfunction in glioblastoma: Applying a new framework. Clinical Cancer Research. 2018;24:3792-3802. https://doi.org/10.1158/1078-0432.CCR-18-0047
  40. Wang T, Zhang H, Han Y, Zheng Q, Liu H, Han M, Li Z. Reversing t cell dysfunction to boost glioblastoma immunotherapy by paroxetine-mediated grk2 inhibition and blockade of multiple checkpoints through biomimetic nanoparticles. Advanced Science. 2023;10:e2204961. https://doi.org/10.1002/advs.202204961
  41. Cantoni GL. The nature of the active methyl donor formed enzymatically from l-methionine and adenosinetriphosphate1,2. Journal of the American Chemical Society. 1952;74(11):2942-2943.
  42. Bottiglieri T, Laundy M, Martin R, Carney MW, Nissenbaum H, Toone BK, Johnson AL, Reynolds EH. S-adenosylmethionine influences monoamine metabolism. Lancet. 1984;2:224.  https://doi.org/10.1016/s0140-6736(84)90507-5
  43. Janicak PG, Lipinski J, Davis JM, Altman E, Sharma RP. Parenteral s-adenosyl-methionine (same) in depression: Literature review and preliminary data. Psychopharmacology Bulletin. 1989;25:238-242. 
  44. Mosca L, Pagano C, Tranchese RV, Grillo R, Cadoni F, Navarra G, Coppola L, Pagano M, Mele L, Cacciapuoti G, Laezza C, Porcelli M. Antitumoral activity of the universal methyl donor s-adenosylmethionine in glioblastoma cells. Molecules. 2024;29(8):1708. https://doi.org/10.3390/molecules29081708
  45. Linde K, Berner M, Egger M, Mulrow C. St john’s wort for depression: Meta-analysis of randomised controlled trials. The British Journal of Psychiatry. 2005;186:99-107.  https://doi.org/10.1192/bjp.186.2.99
  46. Dong X, Zeng Y, Zhang Z, Fu J, You L, He Y, Hao Y, Gu Z, Yu Z, Qu C, Yin X, Ni J, Cruz LJ. Hypericin-mediated photodynamic therapy for the treatment of cancer: A review. Journal of Pharmacy and Pharmacology. 2021;73:425-436.  https://doi.org/10.1093/jpp/rgaa018
  47. Couldwell WT, Surnock AA, Tobia AJ, Cabana BE, Stillerman CB, Forsyth PA, Appley AJ, Spence AM, Hinton DR, Chen TC. A phase 1/2 study of orally administered synthetic hypericin for treatment of recurrent malignant gliomas. Cancer. 2011;117:4905-4915. https://doi.org/10.1002/cncr.26123
  48. Ghiasvand S, Javidi MA, Mohammadian A, Mousavi SA, Shahriari F, Alavian F. Transcriptome analysis evinces anti-neoplastic mechanisms of hypericin: A study on u87 glioblastoma cell line. Life Sciences. 2021;266:118874. https://doi.org/10.1016/j.lfs.2020.118874
  49. Doroshenko A, Tomkova S, Kozar T, Stroffekova K. Hypericin, a potential new bh3 mimetic. Frontiers in Pharmacology. 2022;13:991554. https://doi.org/10.3389/fphar.2022.991554
  50. Hovan A, Pevna V, Huntosova V, Miskovsky P, Bano G. Singlet oxygen lifetime changes in dying glioblastoma cells. Photochemistry and Photobiology. 2024;100:159-171.  https://doi.org/10.1111/php.13828
  51. Han Y, Chen J, Zou D, Zheng P, Li Q, Wang H, Li P, Zhou X, Zhang Y, Liu Y, Xie P. Efficacy of ketamine in the rapid treatment of major depressive disorder: A meta-analysis of randomized, double-blind, placebo-controlled studies. Neuropsychiatric Disease and Treatment. 2016;12:2859-2867. https://doi.org/10.2147/NDT.S117146
  52. Niwa H, Furukawa KI, Seya K, Hirota K. Ketamine suppresses the proliferation of rat c6 glioma cells. Oncology Letters. 2017;14:4911-4917. https://doi.org/10.3892/ol.2017.6806
  53. Edstrom S, Hellquist BN, Sandstrom M, Sadanandan SA, Bjorkblom B, Melin B, Sjoberg RL. Antidepressants and survival in glioma-a registry-based retrospective cohort study. Neuro-Oncology Practice. 2024;11:125-131.  https://doi.org/10.1093/nop/npad057
  54. Seliger C, Oppong FB, Lefranc F, Chinot O, Stupp R, Nabors B, Gorlia T, Weller M. Association of antidepressant drug use with outcome of patients with glioblastoma. International Journal of Cancer. 2023;152:1348-1359. https://doi.org/10.1002/ijc.34344

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.